The US Food and Drug Administration (FDA) recently authorised Novavax’s COVID-19 vaccine as a booster for adults.
The booster authorisation applies to people who are unable to get updated Omicron-tailored boosters, or those who would choose not to receive any other booster dose of a vaccine.
The regulator’s decision is in addition to the earlier clearance for the vaccine as a primary two-shot regimen for those aged 12 years and above.
The company, however, has been struggling with sales of the vaccine, and, in August, had halved its full-year revenue forecast, saying it does not expect further sales of its COVID-19 shot in the US this year.
Edits by EP News Bureau